Rejuveinix Mitigates Sepsis-Associated Oxidative Stress in the Brain of Mice: Clinical Impact Potential in COVID-19 and Nervous System Disorders
暂无分享,去创建一个
F. Uckun | K. Şahin | M. Tuzcu | M. Volk | M. Gitterle
[1] F. Uckun,et al. Rejuveinix Shows a Favorable Clinical Safety Profile in Human Subjects and Exhibits Potent Preclinical Protective Activity in the Lipopolysaccharide-Galactosamine Mouse Model of Acute Respiratory Distress Syndrome and Multi‐Organ Failure , 2020, Frontiers in Pharmacology.
[2] G. Cami-Kobeci,et al. COVID-19 and Parkinson’s Disease: Shared Inflammatory Pathways Under Oxidative Stress † , 2020, Brain sciences.
[3] C. Ghosh,et al. COVID-19-Associated Neurological Disorders: The Potential Route of CNS Invasion and Blood-Brain Barrier Relevance , 2020, Cells.
[4] Amitabh,et al. Brain and COVID-19 Crosstalk: Pathophysiological and Psychological Manifestations. , 2020, ACS chemical neuroscience.
[5] A. Gorji,et al. A Review on the Neurological Manifestations of COVID-19 Infection: a Mechanistic View , 2020, Molecular Neurobiology.
[6] Z. Memish,et al. Fragile Endothelium and Brain Dysregulated Neurochemical Activity in COVID-19 , 2020, ACS chemical neuroscience.
[7] Giulio Sancini,et al. Considerations around the SARS-CoV-2 Spike Protein with Particular Attention to COVID-19 Brain Infection and Neurological Symptoms , 2020, ACS chemical neuroscience.
[8] M. Raftery,et al. Devilishly radical NETwork in COVID-19: Oxidative stress, neutrophil extracellular traps (NETs), and T cell suppression , 2020, Advances in Biological Regulation.
[9] H. Niazkar,et al. The neurological manifestations of COVID-19: a review article , 2020, Neurological Sciences.
[10] F. Uckun. Reducing the Fatality Rate of COVID-19 by Applying Clinical Insights From Immuno-Oncology and Lung Transplantation , 2020, Frontiers in Pharmacology.
[11] K. Hashimoto,et al. Nervous system involvement after infection with COVID-19 and other coronaviruses , 2020, Brain, Behavior, and Immunity.
[12] Arash Azhideh. COVID-19 Neurological Manifestations , 2020 .
[13] C. Cheung,et al. Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) , 2020, Journal of General Internal Medicine.
[14] Z. Memish,et al. Reducing mortality from 2019-nCoV: host-directed therapies should be an option , 2020, The Lancet.
[15] B. Ahmed,et al. COVID-19 and Parkinson’s Disease: Shared Inflammatory Pathways Under Oxidative Stress † , 2020 .
[16] F. Uckun,et al. Clinical impact potential of Rejuveinix (RJX) for prevention of fatal acute respiratory distress syndrome (ARDS) and multi-organ failure in COVID-19 patients. , 2020 .
[17] F. Uckun,et al. Rationale for a randomized, placebo-controlled, Phase 2 study of Rejuveinix (RJX) in COVID-19 patients with acute lung injury and hypoxemic respiratory failure , 2020 .